Twin Tree Management’s Sarepta Therapeutics SRPT Stock Holding History

Twin Tree Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-261,900	Closed	-$31.8M	–	1904
2024 Q4	$31.8M	Sell	261,900 -321,600	-55%	-$39.4M	0.06%	307
2024 Q3	$72.9M	Buy	583,500 +182,900	+46%	+$25.3M	0.14%	111
2024 Q2	$63.3M	Buy	+400,600	New	+$51.5M	0.14%	134
2023 Q4	–	Sell	-41,700	Closed	-$5.05M	–	1578
2023 Q3	$5.05M	Sell	41,700 -170,700	-80%	-$19.3M	0.01%	674
2023 Q2	$24.3M	Buy	+212,400	New	+$27.4M	0.04%	361
2020 Q1	–	Sell	-31,700	Closed	-$4.09M	–	1605
2019 Q4	$4.09M	Hold	31,700	–	–	0.01%	554
2019 Q3	$2.39M	Buy	+31,700	New	+$3.74M	0.01%	648

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Twin Tree Management's SRPT Position: Q1 2025 in Review

Twin Tree Management sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 61,658 shares — an estimated $7.5M sold.

Twin Tree Management first reported a position in SRPT in Q3 2019 and held it in 6 quarters. The position peaked at $13.4M in Q3 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Twin Tree Management reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Twin Tree Management sold 61,658 Sarepta Therapeutics shares in Q1 2025, an estimated $7.5M.
Twin Tree Management first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 6 quarters.
Twin Tree Management's Sarepta Therapeutics position peaked at $13.4M in Q3 2024.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Twin Tree Management's 13F filing for Q1 2025, filed 15 May 2025.